ATE402945T1 - Neuer steroidagonist für fxr - Google Patents

Neuer steroidagonist für fxr

Info

Publication number
ATE402945T1
ATE402945T1 AT05715596T AT05715596T ATE402945T1 AT E402945 T1 ATE402945 T1 AT E402945T1 AT 05715596 T AT05715596 T AT 05715596T AT 05715596 T AT05715596 T AT 05715596T AT E402945 T1 ATE402945 T1 AT E402945T1
Authority
AT
Austria
Prior art keywords
fxr
steroidagonist
new
solvates
chem
Prior art date
Application number
AT05715596T
Other languages
English (en)
Inventor
Roberto Pellicciari
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE402945T1 publication Critical patent/ATE402945T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT05715596T 2004-02-26 2005-02-28 Neuer steroidagonist für fxr ATE402945T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04004408A EP1568706A1 (de) 2004-02-26 2004-02-26 Neuer Steroid-Agonist für FXR

Publications (1)

Publication Number Publication Date
ATE402945T1 true ATE402945T1 (de) 2008-08-15

Family

ID=34745911

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05715596T ATE402945T1 (de) 2004-02-26 2005-02-28 Neuer steroidagonist für fxr

Country Status (11)

Country Link
US (1) US7812011B2 (de)
EP (2) EP1568706A1 (de)
AT (1) ATE402945T1 (de)
CY (1) CY1108455T1 (de)
DE (1) DE602005008611D1 (de)
DK (1) DK1776377T3 (de)
ES (1) ES2313305T3 (de)
PL (1) PL1776377T3 (de)
PT (1) PT1776377E (de)
SI (1) SI1776377T1 (de)
WO (1) WO2005082925A2 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002308295B2 (en) 2001-03-12 2007-08-23 Intercept Pharmaceuticals, Inc. Steroids as agonists for FXR
SI2712617T1 (sl) 2004-03-12 2017-01-31 Intercept Pharmaceuticals, Inc. Zdravljenje fibroze z uporabo Fxr ligandov
US10987362B2 (en) 2004-03-12 2021-04-27 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using FXR ligands
ITMI20050912A1 (it) * 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
EP2040713B1 (de) * 2006-06-27 2014-06-18 Intercept Pharmaceuticals Inc. Gallensäurederivate als fxr-liganden zur prävention oder behandlung fxr-vermittelter erkrankungen oder leiden
EP1886685A1 (de) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methoden, Verwendungen und Zusammensetzungen zur Modulation der Replikation von HCV durch Aktivierung oder Hemmung des Farnesoid X Rezeptors
CA2928178C (en) 2007-01-19 2019-09-10 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
US8338628B2 (en) * 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
EP2324046B1 (de) 2008-07-30 2014-09-03 Intercept Pharmaceuticals, Inc. Tgr5-modulatoren und anwendungsverfahren dafür
NO2698375T3 (de) 2008-11-19 2018-07-21
EP2379081B1 (de) 2008-12-19 2013-03-20 Royal College of Surgeons in Ireland Behandlung von diarrhö
EP2255813A1 (de) * 2009-05-29 2010-12-01 The Royal College of Surgeons in Ireland Ursodeoxycholsäurederivate zur Behandlung von Diarrhöe
US8258485B2 (en) * 2010-08-30 2012-09-04 Media Lario Srl Source-collector module with GIC mirror and xenon liquid EUV LPP target system
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
CA2877122C (en) 2012-06-19 2020-04-28 Intercept Pharmaceuticals, Inc. Preparation, uses and solid forms of obeticholic acid
KR102068381B1 (ko) 2012-10-26 2020-01-20 인터셉트 파마슈티컬즈, 인크. 담즙산 유도체의 제조 방법
EP2997035B8 (de) * 2013-05-14 2018-05-23 Intercept Pharmaceuticals, Inc. 11-hydroxyl-6-substituierte-derivative von gallensäuren und aminosäurekonjugate davon als farnesoid-x-rezeptormodulatoren
CN105636984A (zh) 2013-06-13 2016-06-01 法斯特弗沃德制药有限公司 用于治疗慢性炎症和预防胃肠道癌或纤维化的cd40信号转导抑制剂和其他化合物，该其他化合物是胆汁酸、胆汁酸衍生物、tgr5受体激动剂、fxr激动剂或其组合
DK3043865T3 (da) 2013-09-11 2021-02-01 Univ Claude Bernard Lyon Fremgangsmåder og farmaceutiske sammensætningr til behandlingen af hepatitis b-virusinfektion
US10202601B2 (en) 2013-11-22 2019-02-12 Mina Therapeutics Limited C/EBPα short activating RNA compositions and methods of use
EP3149019B1 (de) 2014-05-29 2019-12-04 Bar Pharmaceuticals S.r.l. Cholanderivate zur verwendung bei der behandlung und/oder prävention von fxr- und tgr5/gpbar1-vermittelten krankheiten
HK1243930A1 (zh) 2014-11-06 2018-07-27 英安塔制药有限公司 作爲fxr/tgr5激动剂的胆汁酸类似物和其使用方法
PL3221331T3 (pl) 2014-11-19 2020-03-31 NZP UK Limited Steroidy, 6-alkilo-7-hydroksy-4-en-3-ony jako związki pośrednie do wytwarzania steroidowych modulatorów fxr
TWI688571B (zh) 2014-11-19 2020-03-21 英商Ｎｚｐ英國有限公司 化合物（四）
WO2016079518A1 (en) 2014-11-19 2016-05-26 Dextra Laboratories Limited 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators
CN107108688B (zh) 2014-11-19 2019-10-29 Nzp英国有限公司 作为制备类固醇FXR调节剂的中间体的6α-烷基-3,7-二酮类固醇
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
MX2017006833A (es) 2014-11-26 2018-02-13 Enanta Pharm Inc Análogos de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
CN107405325B (zh) 2015-02-06 2021-11-12 英特塞普特医药品公司 用于组合疗法的药物组合物
MX2017010376A (es) 2015-02-11 2017-12-20 Enanta Pharm Inc Análogos de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
CN105985396A (zh) * 2015-02-16 2016-10-05 苏州泽璟生物制药有限公司 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
MX379579B (es) 2015-03-31 2025-03-11 Enanta Pharm Inc Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para su uso.
AU2016246524B2 (en) 2015-04-07 2021-04-01 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions for combination therapy
CN105777836A (zh) * 2015-04-09 2016-07-20 厦门蔚扬药业有限公司 奥贝胆酸的多晶型物及其制备方法
CN111574577B (zh) * 2015-04-29 2025-02-25 正大天晴药业集团股份有限公司 鹅去氧胆酸衍生物
EP3124080A1 (de) 2015-07-28 2017-02-01 Merz Pharma GmbH & Co. KGaA Semisynthetische gallsäurederivate zur injektionslipolyse
CN105175473B (zh) * 2015-08-19 2018-12-21 丽珠医药集团股份有限公司 一种奥贝胆酸晶型i及其制备方法、药物组合物和用途
CN106632564B (zh) * 2015-10-30 2021-04-13 苏州泽璟生物制药股份有限公司 奥贝胆酸盐及其无定形物和药物组合物
CN106749466B (zh) * 2015-11-23 2019-05-21 南京济群医药科技股份有限公司 一种高纯度奥贝胆酸的制备方法
CN105315320B (zh) * 2015-11-30 2017-03-08 山东省药学科学院 一种制备奥贝胆酸的方法
CN106810586A (zh) * 2015-12-01 2017-06-09 中美华世通生物医药科技（武汉）有限公司 奥贝胆酸晶型ⅱ及其制备方法和用途
CN106810587A (zh) * 2015-12-01 2017-06-09 中美华世通生物医药科技（武汉）有限公司 制备无定型奥贝胆酸的方法
AU2017213032B2 (en) 2016-01-28 2021-01-07 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Steroid derivative FXR agonist
US20170233431A1 (en) 2016-02-17 2017-08-17 City Of Hope Bile acid derivatives and methods for synthesis and use
US10323061B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof
WO2017147137A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
WO2017147159A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
WO2017167233A1 (zh) * 2016-03-31 2017-10-05 江苏恒瑞医药股份有限公司 一种奥贝胆酸的新结晶形式及其制备方法
TW201738254A (zh) * 2016-04-19 2017-11-01 英特賽普醫藥品公司 奧貝膽酸及其衍生物之製備方法
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
EA038580B9 (ru) * 2016-05-18 2021-10-05 Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. Агонист fxr, представляющий собой производное стероидов
WO2017207648A1 (en) 2016-05-31 2017-12-07 Bionice, S.L.U Process and intermediates for the preparation of obeticholic acid and derivatives thereof
TW201802103A (zh) * 2016-07-13 2018-01-16 江蘇恆瑞醫藥股份有限公司 一種奧貝膽酸及其中間體的製備方法
CN110121347A (zh) 2016-11-29 2019-08-13 英安塔制药有限公司 制备磺酰脲胆汁酸衍生物的方法
US10472386B2 (en) 2017-02-14 2019-11-12 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR agonists and methods of use thereof
JP7618384B2 (ja) 2017-02-21 2025-01-21 ジェンフィ Ｐｐａｒアゴニストとｆｘｒアゴニストとの組合せ
US20210139528A1 (en) * 2017-03-08 2021-05-13 Intercept Pharmaceuticals, Inc. Crystalline forms of obeticholic acid
US20210085662A1 (en) 2017-03-30 2021-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
MX388300B (es) 2017-04-07 2025-03-19 Enanta Pharm Inc Proceso para la preparación de derivados de ácidos biliares de sulfonil carbamato
CN110662743B (zh) 2017-05-26 2022-09-30 石药集团中奇制药技术（石家庄）有限公司 作为fxr受体激动剂的内酰胺类化合物
CN109021056B (zh) * 2017-06-09 2021-03-09 博瑞生物医药（苏州）股份有限公司 法尼酯x受体激动剂
WO2019048631A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited SMALL HNF4A ACTIVATOR RNA COMPOSITIONS AND METHODS OF USE
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
WO2020039449A1 (en) 2018-08-24 2020-02-27 Solara Active Pharma Sciences Limited An improved process for the preparation of obeticholic acid and intermediates used in the process thereof
US12215098B2 (en) * 2018-11-26 2025-02-04 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Solid form, crystalline form, and crystal form a of FXR agonist, and preparation method and application thereof
CA3142358A1 (en) 2019-05-30 2020-12-03 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
KR20220035365A (ko) 2019-07-18 2022-03-22 엔요 파마 인터페론의 부작용을 감소시키는 방법
EP4011899A4 (de) * 2019-08-06 2022-09-28 Huang, Qiang Deoxycholsäureverbindungen, pharmazeutische zusammensetzungen und verwendungen davon
CN114945361A (zh) 2020-01-15 2022-08-26 法国国家卫生及研究医学协会 Fxr激动剂在治疗丁型肝炎病毒感染中的用途
AU2022209084A1 (en) 2021-01-14 2023-08-10 Centre Leon Bérard Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
WO2022229302A1 (en) 2021-04-28 2022-11-03 Enyo Pharma Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1223313B (it) * 1987-10-20 1990-09-19 Gipharmex Spa Derivati di acidi biliari loro preparazione e composizioni farmaceutiche che li contengono
WO2003080803A2 (en) * 2002-03-21 2003-10-02 Smithkline Beecham Corporation Methods of using farnesoid x receptor (fxr) agonists
ITMI20021532A1 (it) 2002-07-12 2004-01-12 Roberto Pellicciari Composti chimici

Also Published As

Publication number Publication date
EP1776377B1 (de) 2008-07-30
PL1776377T3 (pl) 2009-02-27
DE602005008611D1 (de) 2008-09-11
US20080039435A1 (en) 2008-02-14
EP1568706A1 (de) 2005-08-31
US7812011B2 (en) 2010-10-12
WO2005082925A2 (en) 2005-09-09
PT1776377E (pt) 2008-11-11
WO2005082925A3 (en) 2005-11-24
EP1776377A2 (de) 2007-04-25
ES2313305T3 (es) 2009-03-01
CY1108455T1 (el) 2014-04-09
SI1776377T1 (sl) 2009-04-30
DK1776377T3 (da) 2008-11-24

Similar Documents

Publication Publication Date Title
ATE402945T1 (de) Neuer steroidagonist für fxr
NL300877I2 (nl) obeticholzuur
SE0202465D0 (sv) New compounds
ATE523507T1 (de) Piperidin-gpcr-agonisten
BRPI0518360A2 (pt) composto e sais farmaceuticamente aceitÁveis do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar um composto ou um sal farmaceuticamente aceitÁvel do mesmo
BRPI0615705A2 (pt) processo para preparar um composto, e, composto
ZA200700765B (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
EA200970372A1 (ru) Ингибитор развития болезни альцгеймера, содержащий гетероциклическое соединение
CY1107141T1 (el) Μεθοδος για την παρασκευη της 1-(2s,3s)-2-βενζυδρυλ-ν-(5-τριτ.-βουτυλ-2-μεθοξυβενζυλ)κινουκλιδιν-3-αμινης
NO330968B1 (no) Ny fremgangsmate for syntesen av (1S)-4,5-dimetoksy-1-(metylaminometyl)-benzocyklobutan og addisjonssalter derav, og anvendelse i syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre
EP1951731A4 (de) Azacyclohexanderivate als inhibitoren von stearoyl-coenzym-a-delta-9-desaturase
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
ECSP055886A (es) Derivados de isoindolina
EA200970124A1 (ru) Производные 2-арилиндола в качестве ингибиторов npges-1
DE602005023197D1 (de) -muscarinrezeptors
GEP20084494B (en) New heterocyclic carboxylic acid amide derivatives
NO20080839L (no) Isotopsubstituerte protonpumpeinhibitorer
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
EA200801365A1 (ru) Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины
EA200800324A1 (ru) Новый способ получения солей тиотропия
ECSP034708A (es) Nueva sal de benzoilguanidina
EA200801139A1 (ru) Композиция для аэрозольной ингаляции
NO20081529L (no) Naftyridinderivater
EA200901229A1 (ru) Новый способ получения левоцетиризина и его промежуточных соединений
UY31668A1 (es) "ligando de receptor d2-078"

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1776377

Country of ref document: EP